News

FDA Offers New Resource on Biosimilars for Health Care Providers


 

References

A free continuing education course, FDA Overview of Biosimilar Products, is available to health care providers. The course was designed to help providers strengthen their knowledge and understanding of biosimilars and interchangeable products, which are not the same as generic products.

In February 2015, the FDA approved the first biosimilar in the U.S., and there is growing interest in biosimilars in the pharmaceutical industry. The new course will help health care professionals understand how a biosimilar can be prescribed and dispensed, and how and when an interchangeable product can be substituted for another biological product.

The course is available to health professionals on FDA’s CDERLearn website and can be completed on a tablet for those not at their desktop computer. Click for more information.

Recommended Reading

Patient Organizations May Apply to Join Natural History Study Project
MDedge Endocrinology
Rare Disease Community Prepares for Worldwide Observance of Rare Disease Day
MDedge Endocrinology
Omnibus Spending Bill Includes Provisions Important to the Rare Disease Community
MDedge Endocrinology
FDA Invites Patient Organizations to Organize Public Meetings to Enhance Awareness of Their Needs
MDedge Endocrinology
NIH Releases Its Strategic Plan
MDedge Endocrinology
Baylor College of Medicine and National Urea Cycle Disorders Foundation Collaborate on Preclinical Research
MDedge Endocrinology
Fat Disorders Research Society Conference to Take Place April 8-10
MDedge Endocrinology
Endocrine Society issues first-ever guidelines for primary adrenal insufficiency
MDedge Endocrinology
Human gene editing consensus study underway
MDedge Endocrinology
EHR Report: How Zika virus reveals the fault in our EHRs
MDedge Endocrinology